Novartis: Hematologic Neoplasms trials

The registry lists 18 Hematologic Neoplasms studies with Novartis as lead sponsor. 1 are open to participants now and 13 have results posted.

Phase 1 5Phase 2 11Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Extension Study for Patients Previously Enrolled in Studies With PelabresibRecruitingNCT06401356Phase 3
• Ceritinib Rare Indications Study in ALK+ TumorsTerminatedNCT02465528Phase 2Results posted
• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)CompletedNCT02187783Phase 2Results posted
• Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)TerminatedNCT02186821Phase 2Results posted
• BGJ398 for Patients With Tumors With FGFR Genetic AlterationsTerminatedNCT02160041Phase 2Results posted
• LDE225 for Patients With PTCH1 or SMO Mutated TumorsTerminatedNCT02002689Phase 2Results posted
• BKM120 for Patients With PI3K-activated TumorsCompletedNCT01833169Phase 2Results posted
• Dovitinib for Patients With Tumor Pathway Activations Inhibited by DovitinibCompletedNCT01831726Phase 2Results posted
• Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the InvestigatorCompletedNCT01802879Phase 2Results posted
• Continuation Study of the Oral AKT Inhibitor GSK2110183CompletedNCT01531894Phase 2Results posted
• Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapyCompletedNCT00790036Phase 3Results posted
• Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)TerminatedNCT00519090Phase 3Results posted
• A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)CompletedNCT00471497Phase 3Results posted
• Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic ImpairmentCompletedNCT05599932Phase 1
• A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological MalignanciesCompletedNCT01830010Phase 1
• Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple MyelomaCompletedNCT01428492Phase 1
• Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer PatientsCompletedNCT00526045Phase 1/2